Trade Mark Journal No.2026/010 6 March 2026

UK00004333191 31 January 2026 (5)

Nugenyx

Class 5: Synthetic peptides for pharmaceutical purposes; Protein synthesis inhibitors; Endogenous antigens; Antibodies; Capsules made of dendrimer-based polymers, for pharmaceuticals; Antigens; Exogenous antigens; Protein supplements; Autoantigens; Antiviral prodrugs; Immunostimulants; Protein supplements for animals; Mycolic acid synthesis inhibitors; RNA synthesis inhibitors; Anti-neoplastic preparations from hormones and antagonists; Neoantigens; Pharmaceutical preparations and substances with anti-inflammatory properties; Immunomodulators; DNA synthesis inhibitors; Anti-cancer preparations from hormones and antagonists; Anti-oxidants comprising enzymes; Whey protein dietary supplements; Food supplements consisting of amino acids; Alkaloids used as analgesics; Anti-inflammatory gels; Amino acid preparations for pharmaceutical use; Pharmaceutical preparations and substances with analgesic properties; Radiotherapeutic hormones; Tumour antigens; Alkaloids used as stimulants; Pharmaceutical preparations containing stem cells; Antitoxins; Immunotherapeutic agents for bacterial infections; Blood protein fractions; Folic acid synthesis inhibitors; Protein dietary supplements.

Sabri Gazail